NTT Electronics expands its 400G Coherent DSP line-up into Data Center Interconnects and longer reach networks
NTT Electronics Corporation, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced addition of a low power consumption 400G Coherent DSP to its product portfolio for enabling multi-rate Ethernet transport and applications far beyond Data Center Interconnects. The new DSP ExaSPEED400-R focuses on 400ZR and OpenZR+ interoperable QSFP-DD applications, and achieves 20% less power consumption than its upper-compatible ExaSPEED400 for CFP2-DCO applications.
The new ExaSPEED400-R supports both OIF 400ZR and OpenZR+ MSA 100G-400G specification at the line side, and provides Ethernet transport with 8x25G-NRZ and 8x50G-PAM4 interfaces at the client side. It supports fully flexible Ethernet formats: 1x100GE, 2x100GE/1x200GE, 3x100GE, and 4x100GE/2x200GE/1x400GE.
“This is a very exciting development enabling the use of a low-power DSP in interoperable coherent QSFP-DD modules for an expansion of the application space by cloud network operations and service providers,” said Atul Srivastava, Co-chair of the OpenZR+ MSA Group.
At ECOC 2022, NTT Electronics will show a video demonstration of QSFP-DD module interoperability at 400G OpenZR+ including over 1000km straight fiber transmission, with the support of its QSFP-DD partners Fujitsu Optical Components Ltd., Molex LLC, and NEC Corporation.
Mogi Masahiro, President, Fujitsu Optical Components America Inc, commented as below. “For many years, from the inception of the coherent optical transmission technology, NTT Electronics and Fujitsu Optical Components (FOC) have established a successful partnership to bring the most advanced optical transceiver products to market. We are now very pleased that interoperable coherent transmission has been achieved successfully between FOC’s QSFP-DD optical transceiver, incorporating NTT Electronics’ new ExaSPEED400-R DSP chip, and multi-vendors’ QSFP-DD transceivers. Using FOC’s optical transceiver which enables transmission distance extension with low-power consumption, we are very pleased to be contributing to the ecosystem of interoperable coherent transceivers for data center and service provider networks.”
“Molex is focused on expanding the reach for data center interconnect beyond 120km, recognizing the industry need for significantly improved performance,” said Joseph Chon, director, Coherent Technology and Product Line Management, Molex Optoelectronics. “Collaborating with NTT Electronics and its module partners has accelerated the overall business opportunity for the interoperable QSFP-DD Interconnect Systems and we look forward to supporting evolving customer requirements in this space.”
“We have been developing and producing the state-of-art digital coherent transceivers for more than a decade.” said Akio Goto, General Manager of Photonic Device Development Department, NEC, “And now, as part of continuous collaborations to expand the digital coherent business with NTT Electronics, we have succeeded in developing QSFP-DD, competitive in the market, by using our technical assets and experience. We are accelerating their deployments for various markets.”
ExaSPEED400-R is now ramping up its production volume.
About NTT Electronics
NTT Electronics has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond systems, ROADM components and FTTH networks. Since 2012 NTT Electronics has been delivering its flag-ship 100G coherent DSP that has been widely adopted in the industry. NTT Electronics is headquartered in Yokohama, Japan with offices in Milan, Italy, San Jose, CA, and Shenzhen, China. For more information, go to http://www.ntt-electronics.com/en/about/overview.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005082/en/
Contact information
NTT Electronics Contacts
Daniele Fadini
Managing Director
NTT Electronics Europe S.r.l
Tel : +39-02-49537430
Email: info@ntt-el-eu.com
Atul Srivastava
Chief Technical Officer
NTT Electronics America, Inc.
Tel: +1-201-566-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom